Arthur Sterin
Overview
Explore the profile of Arthur Sterin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
20
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sicre de Fontbrune F, Chevillon F, Fahd M, Desseaux K, Poire X, Forcade E, et al.
Br J Haematol
. 2024 Aug;
PMID: 39159950
Modalities and timing of haematopoietic stem cell transplant (HSCT) in patients with GATA2 deficiency are still subject to debate. On June 2022, 67 patients (median age 20.6 years) underwent a...
2.
Hussein-Agha R, Kannengiesser C, Lainey E, Marcais A, Srour M, Sterin A, et al.
Bone Marrow Transplant
. 2024 Jul;
59(10):1428-1432.
PMID: 39080469
While HSCT is the only curative option for patients with short telomere syndromes (STSs) and severe bone marrow failure (BMF) or myeloid malignancies (MM), their increase sensitivity to conditioning regimen...
3.
Le Calvez B, Jullien M, Dalle J, Renard C, Jubert C, Sterin A, et al.
Hemasphere
. 2024 Jul;
8(7):e120.
PMID: 38978638
For most patients with childhood myelodysplastic syndrome (cMDS), allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only curative option. In the case of increased blasts (cMDS-IB), the benefit of pretransplant...
4.
Petit A, Neven B, Min V, Mahlaoui N, Moshous D, Castelle M, et al.
Transplant Cell Ther
. 2023 Jun;
29(9):582.e1-582.e6.
PMID: 37321401
The overall survival rate after hematopoietic stem cell transplantation (HSCT) for inborn errors of immunity (IEI) has improved considerably, and its indications have broadened. As a consequence, addressing the issue...
5.
Leblond P, Tresch-Bruneel E, Probst A, Neant N, Solas C, Sterin A, et al.
Cancers (Basel)
. 2023 Apr;
15(7).
PMID: 37046681
Preclinical data support the activity of celecoxib and fluvastatin in high-grade (HGG) and low-grade gliomas (LGG). A phase I trial (NCT02115074) was designed to evaluate the safety of this combination...
6.
Picard M, Sterin A, Bay J, Courbon C, Moreau A, Paul F, et al.
Bull Cancer
. 2022 Jan;
110(2S):S123-S131.
PMID: 35094839
The immune effector cell-associated syndrome (ICANS) has been described as the second most frequent specific complication following CAR-T cell therapy. The median time to the onset of neurological symptoms is...
7.
Tudesq J, Yakoub-Agha M, Bay J, Courbon C, Paul F, Picard M, et al.
Bull Cancer
. 2021 Dec;
110(2S):S116-S122.
PMID: 34895696
The use of chimeric antigen receptor T cells (CAR-T) has increased since their approval in the treatment of several relapsed/refractory B cell malignancies. The management of their specific toxicities, such...
8.
Paul F, Vicente C, Courbon C, Moreau A, Picard M, Pochon C, et al.
Bull Cancer
. 2021 Dec;
108(12S):S90-S97.
PMID: 34876272
Infections occurring after CAR T-cells are a common complication. At the acute phase of treatment following CAR T-cell infusion, the exact incidence of infections is unknown given the overlapping symptoms...
9.
Pochon C, Courbon C, Bay J, Moreau A, Paul F, Picard M, et al.
Bull Cancer
. 2021 Nov;
108(12S):S98-S103.
PMID: 34802718
CAR-T cells are an innovative treatment for an increasing number of patients, particularly since the extension of their indication to mantle lymphoma and multiple myeloma. Several complications of CAR T-cell...
10.
Bataller A, Guijarro F, Caye-Eude A, Strullu M, Sterin A, Molina O, et al.
Blood Adv
. 2021 Oct;
5(24):5617-5620.
PMID: 34638131
No abstract available.